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all possible types of multi-component apheresis. To en-
sure the comparability of the data, the AGHV adopted 
the ‘Standard for Surveillance of Complications Related 
to Blood Donation’ from the International Society for 
Blood Transfusion in cooperation with the International 
Haemovigilance Network (IHN) and the American Asso-
ciation of Blood Banks for AE acquisition and automated 
evaluation. The registry is embedded in a prospective 
observational multi-centre study with a study period of 7 
years. Results: A preliminary evaluation encompassed 
the time period from January, 2012 to December, 2015. 
During this time, the system proved to be safe and sta-
ble. Out of approximately 345,000 haemaphereses 
16,477 AEs were reported (4.9%) from 20 participating 
centres. The majority of AEs occurred in PLSs (63%), fol-
lowed by PLT (34.5%) and SC (2.2%). Blood access inju-
ries (BAI) accounted for about 55% of the supplied AEs, 
whereas citrate toxicity symptoms, vasovagal reactions 
and technical events (e.g. disposable leakages, software 
failures) rather equally affected haemaphereses at 
8–15%. Out of 12,348 finalized AEs, 8,759 (70.1%) were 
associated with a procedure-related break-off, with BAI 
being the prevailing cause (5,463/8,759; 62.4%). An auto-
mated centre- and procedure-specific AE evaluation ac-
cording to the latest IHN standard and AGHV pre-set-
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Summary
Background: Currently, there is an extensive but highly 
inconsistent body of literature regarding donor adverse 
events (AEs) in haemapheresis. As the reports diverge 
with respect to types and grading of AEs, apheresis pro-
cedures and machines, the range of haemapheresis- 
related AEs varies widely from about 0.03% to 6.6%. 
Methods: The German Society for Transfusion Medicine 
and Immunohaematology (DGTI) formed a ‘Haemapher-
esis Vigilance Working Party’ (Arbeitsgemeinschaft Hä-
mapheresevigilanz; AGHV) to create an on-line registry 
for comprehensive and comparable AE assessment with 
all available apheresis devices in all types of preparative 
haemapheresis: plasmapheresis (PLS), plateletpheresis 
(PLT), red blood cell apheresis, all kind of leukaphereses 
(autologous/allogeneic blood stem cell apheresis, granu-
locyte apheresis, lymphocyte/monocyte apheresis) and 
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tings is available within a few minutes. Conclusions: An 
on-line electronic platform for comprehensive assess-
ment and centre-specific automated evaluation of AEs in 
haemaphereses has been developed and proved to be 
stable and safe over a period of 4 years.
© 2016 S. Karger GmbH, Freiburg
Introduction
Modern haemapheresis machines enable transfusion medicine 
specialists to rapidly provide a wide variety of different blood com-
ponents for therapeutic use. These include therapeutic plasma, 
classical cellular blood components (i.e., red blood cell or platelet 
concentrates) and more advanced leucocyte preparations such as 
granulocyte concentrates, blood stem cell (SC) concentrates for 
haematopoietic stem cell transplantation (HSCT) or lymphocyte 
collections for treatment of relapsed haematological malignancies 
after HSCT [1–4]. Recently, multi-component apheresis has been 
introduced to increase the number of different blood components 
that can be obtained from a limited donor pool [5]. The number of 
preparative haemaphereses world-wide per year is unknown. How-
ever, in Germany alone in 2014 approximately 2.8 million plasma-
phereses (PLSs) were done to obtain large quantities of plasma (ca. 
2.1 million litres) as source material for industrial purposes or as 
therapeutic plasma. In addition, about 352,000 platelet concen-
trates from 178,000 plateletphereses (PLTs) as well as SC, granulo-
cyte or lymphocyte components – in total around 11,000 units – 
were prepared for transfusion [6]. Thus complications related to 
haemapheresis procedures in Germany may add to several ten 
thousands adverse events (AEs) per year, even if they would occur 
in about 1–2% of the procedures only.
As preparative haemaphereses are done for more than 60 years 
[7], there is an extensive but inconsistent body of literature regard-
ing donor reactions in haemapheresis [8–24]. As shown in table 1, 
the number of AEs reported in the context of haemapheresis varies 
by two log steps from 0.025% [9] to 5.77% and 6.55% [10, 11]. One 
explanation for this wide range is that some authors included mild, 
clinically insignificant donor reactions (e.g., small haematomas, 
short vasovagal reactions without faint, mild paresthesia [11–14]), 
whereas other reports referred to moderate and severe adverse 
events (SAEs) [14–16] or to SAEs only [9, 17]. But even within the 
donor reaction grading ‘SAE’, the results may vary by 10-fold be-
tween 0.025% [9] and 0.24% [13]. These differences reflect the 
largely diverging study protocols within the literature that affect 
virtually all evaluation parameters. The numbers of evaluated 
aphereses ranged from approximately 5,000–20,000 [12–15, 18] to 
beyond 1 million [9, 11]. The AE categories encompassed blood 
access injuries (BAI) or vasovagal reactions (VVR) as a single eval-
uation parameter in a few papers [16, 18–20], the combination of 
BAI, citrate toxicity (CT) and VVR in other studies [9, 10, 12, 15, 
17, 21, 23] and occasionally a more comprehensive selection in-
cluding BAI, CT, VVR, donor compliance (DC) problems and 
technical (apheresis machine- or apheresis disposable-related) 
events [11, 13]. Further largely diverging parameters refer to the 
choice of the apheresis machines and the apheresis procedures. 
Some authors report data from one specific apheresis procedure 
(e.g., PLS [11] or PLT [13, 15]), whereas others presented AEs from 
different procedures simultaneously such as PLT, single or double 
red blood cell (RA1/RA2) apheresis or multi-component (MC) 
apheresis [9, 14, 18, 20]. Taken these considerations in mind and 
given that haemapheresis is a versatile field with different types of 
apheresis machines and many different technical procedures, it is 
not surprising that the results obtained from AE studies showed a 
wide variance. Another very important point that impairs the com-
parability of the reported AE results was the long lasting absence of 
an internationally accepted standard for assessment and grading of 
AEs in blood donation. Consequently, 11 out of 14 groups devel-
oped own centre-specific systems for assessment and grading of 
AEs [10, 11, 13–16, 19–23]. The remaining groups adopted a 
standard that had been developed by a scientific society [12] or ap-
plied a national (French) standard for donor haemovigilance [9, 
17]. The latter one, however, was designed to assess SAEs only, 
thereby limiting its explanatory power. Taken altogether, there 
were neither uniform study designs nor uniform definitions for 
AEs nor uniform definitions for the grading of the AEs so that a 
direct comparison of AE data between studies was impossible.  
For these obvious reasons there is a need to define, to assess and 
to grade AE in haemapheresis in a manner that allows comparabil-
ity. To accomplish these aims the scientific section ‘Preparative and 
Therapeutic Haemapheresis’ of the German Society for Transfu-
sion Medicine and Immunohaematology (DGTI) formed a ‘Haem-
apheresis Vigilance Working Party’ (Arbeitsgemeinschaft Häma-
pheresevigilanz; AGHV) in 2008. The AGHV was assigned to cre-
ate an easily accessible, easily usable and safe web-based registry for 
comprehensive and comparable AE assessment with all apheresis 
devices, regardless of the manufacturer, in all types of preparative 
haemapheresis: PLS, PLT, red blood cell apheresis (RA), all kind of 
leukaphereses (autologous and allogeneic blood SC apheresis, 
granulocyte (PMN) apheresis, lymphocyte/monocyte (MNC) 
apheresis) and all possible types of multicomponent (MC) aphere-
sis. To ensure the comparability of the data, we adopted the ‘Stan-
dard for Surveillance of Complications Related to Blood Donation’, 
originally released in 2008, and its update, released in December, 
2014 by the International Society of Blood Transfusion (ISBT) 
Working Group on Donor Vigilance in cooperation with the Inter-
national Haemovigilance Network (IHN) and the American Asso-
ciation of Blood Banks for data acquisition and evaluation [24]. 
The registry was embedded in a prospective observational study 
entitled ‘Open Prospective Multicentre Long-Term Study for As-
sessment of Adverse Events in the Context of Haemaphereses by 
Means of an Internet-Based Haemapheresis Vigilance System’ that 
was financed in part by the DGTI and the Swiss Red Cross. The 
study was approved by the Ethics Committee and by the Data Pro-
tection Commissioner of Hanover Medical School. The study is 
registered in ClinicalTrials.gov under NCT01576237.
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Internet-Based Haemapheresis Vigilance System
General Characteristics
The main purpose of this paper is the illustration of our method 
to assess and evaluate donor AEs in haemaphereses. In cooperation 
with Aix Scientifics®, Aachen, Germany, an on-line registry was 
programmed (now available in German, English and French) that 
consists of 6 HTML pages: a title page with a wide range of search 
functions and an access to system-related documents (such as the 
study curriculum, Ethics Committee approval and the user man-
ual), two HTML pages for AE assessment, two  pages for the AE 
evaluation programme and one page for centre-related administra-
tion purposes. The system secures that persons (operators, medical 
staff, physicians, centre administrators) of one specific participat-
ing centre do not have access to the data as well as to the evaluation 
of data of other participating centres. The system administrator 
and the administrators of the participating centres cooperate with 
regard to the restriction of persons (‘users’ such as donor physi-
cians and operators) with access to the system. All individual users 
receive a password that is linked to a certain hierarchy. Operators 
who carry out the haemaphereses usually enter AE data into the 
haemapheresis vigilance system. They have accounts with the low-
est hierarchy level that enables them to save AE data as a ‘draft’. 
Physicians who are responsible for haemapheresis-related donor 
care possess an account with a higher hierarchy level so that they 
are able to review and finalize the AE data of their specific centre. 
Finalized data only are included into the automated evaluation 
programme. The password of the centre-administrator allows 
starting the centre-specific evaluation programme so that the AE 
evaluation will be available together with anonymized data of all 
other participating centres (benchmark data). 
Data Safety
Data safety is performed according European, national, and 
state law. All data are transmitted via https connection to Aix Sci-
entifics and are at least 128-bit-SSL-encrypted. Registered users 
only get access to the system. A password hierarchy automatically 
assigns users to data input only, to review and finalize data, or to 
administrative activities such as centre-related generation of apher-
esis profiles or centre-related data evaluation. The system secures 
that each centre has access to own data, but not to data of other 
centres.
Assessment of AEs
Apheresis Specifications
Following an appropriate password-controlled login, the user is 
guided to the HTML pages ‘Donor data and apheresis specifica-
tion’ (fig.  1, 2) and ‘Complication data’ (fig.  3). The first page 
(fig. 1, overview) consists of an upper part that records donor vari-
ables. Donor data are restricted to a minimum including the spe-
cific donation number, a pseudonymised donor-ID (optional), 
gender, year of birth, height, body weight and donor type (e. g., 
first-time or repeat apheresis donor, see fig. 2a). No other donor 
data have to be given. The conversion of height (cm) to height 
(inch), of body weight (kg) to body weight (lbs) and the calcula-
tions for total donor blood volume (TBV) and donor body mass 
index (BMI) are automatically carried out by the system. To facili-
tate data input, the donation number and the donor-ID code can 
be entered by scanning barcodes. The middle and the lower part of 
the HTML page contain the specifications of the intended aphere-
sis procedure that is involved in the AE. All types of preparative 
haemaphereses are available in form of electronic index cards: PLT 
(fig. 1), PLS (fig. 2a), SC (fig. 2b), haemaphereses for PMN, MNC 
and RA (not shown). If one of these electronic index cards is acti-
vated by a click into the corresponding round button, the card 
opens with all information to the planned apheresis procedure that 
may be relevant for an AE: e.g., single/double needle plateletpher-
esis procedures, volume replacement, CT prophylaxis and the 
number of target products (single-double-triple platelet units for 
transfusion) if they shall be routinely obtained in a PLT (fig. 1), or 
the intended plasma yield of 650–850 ml in a PLS (fig. 2a). Combi-
nations of by-products can also be entered with a selection of 
plasma, of red cells or of plasma plus red cells, if they shall be ob-
tained as a form a MC apheresis in single or double PLT (fig. 1). 
Technical data entry comprehends information to the apheresis 
device including machine and software identification, the lot num-
bers of the machine disposables (tubing sets and citrate/saline flu-
idities) and other specific variables such as the use of additive solu-
tion in PLT (fig.  1). The system is also able to include complex 
haemaphereses such as blood stem cell procedures (fig. 2b). This 
index card provides input positions that are unique for this type of 
apheresis: e.g., details to the donor (autologous or allogeneic), to 
the mobilization of the donor (G-CSF ± plerixafor), to priming 
procedures with red cells or albumin in case of paediatric SC, a 
centre-specific CT prophylaxis regimen, potential by-products and 
a central venous catheter as a possibility for blood access (fig. 2b).
Apheresis Procedure Defaults
As shown in figure 1, many variables characterise apheresis pro-
cedures that are routinely done in a specific apheresis centre. For 
instance, a routine PLT may comprehend 16–18 positions for data 
entry (fig. 1) because each variable may influence the type, the fre-
quency and/or the severity of AEs. The specifications of other 
haemaphereses exhibit a similar extent (PLS, fig.  2a) or are even 
more complex (SC, fig.  2b). To simplify and accelerate the data 
entry for apheresis procedures, the centre administrator is enabled 
to generate electronic apheresis profiles with a large number of de-
faults that characterise a routine apheresis procedure in a specific 
centre. A skilful use of this feature reduces the number of operator-
associated mandatory data entries from 15–20 per apheresis type to 
just two positions: the lot numbers for the apheresis tubing set and 
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
Fig. 1.  Donor data 
and apheresis specifica-
tion HTML page: over-
view, displaying data 
entry possibilities for 
donor and apheresis 
variables (here: a dou-
ble PLT/PLS multi-
component procedure).
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for the ACD-A solution. Of note, apheresis profiles with a large 
number of defaults can be generated for all types of apheresis pro-
cedures, even for procedures as complex as SC aphereses.
Assessment of Complications
The Complication Data HTML page (fig. 3, overview) consists of 
an upper part that records the course of the apheresis. This section 
states whether the AE was associated with a procedure break-off 
and at which point in time the AE occurred (fig. 2). Moreover, the 
course of the AE apheresis is specified with respect to products for 
transfusion that could be obtained despite the break-off and with 
respect to a possible re-infusion of the whole blood / anticoagulant 
mixture that was located in the tubing set when the break-off oc-
curred. The lower part of the Complication Data HTML page con-
D
Fig. 2. a Data entry in PLS: donor data and selected procedure variables. b Specific features for data entry in SC apheresis. Example of an autologous SC apheresis. 
The patient received G-CSF plus plerixafor as mobilization regimen. A central venous catheter was chosen as blood access. Routine CT prophylaxis as well as routine 
plasma collection as a by-product of the procedure can be easily entered, either individually or as a default, if a specific SC apheresis procedure is routinely applied.
E
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
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Fig. 3.  Adverse event data HTML page: overview, displaying data entry possibilities for outcome variables and AE specification. Here: a complex BAI in a triple 
PLT procedure. The first venepuncture developed a haematoma within a few minutes after the start of PLT. After the break-off the machine was newly equipped 
with a second tubing kit and a second venepuncture was done (given as ‘re-puncture’ and ‘change of disposable’ in section ‘6.1.8 Interventions’). The second PLT 
was successful, but due to donor time shortage two out of three planned units of apheresis platelets were obtained only (given in line 4.1 ‘Termination, planned 
products are obtained partly’ and in line 4.3 ‘Therapeutic units for human use’).
Donor Safety in Haemapheresis: Development of 
an Internet-Based Registry for Comprehensive 
Assessment of Adverse Events from Healthy 
Donors
Transfus Med Hemother 2017;44:188–200 195


 
D
Fig. 4. a Assessment of vasovagal reactions. Break-off 45 min after the start of the apheresis due to a mild, but therapy-refractory VVR. b Assessment of technical 
events. Technical AE, here version in German. The event was automatically graded as ‘severe’. In severe reactions the user who finalizes the AE has to state the im-
putability of the AE to the apheresis procedure.
E
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Fig. 5.  Automated 
evaluation according to 
IHN-standard 2014. 
Data from Hanover 
Medical School 2015 as 
an example for the 
function of the system. 
The design of the eval-
uation follows the se-
quence and order of 
the AE as enlisted in 
the IHN standard 2014. 
The percent values 
without brackets repre-
sent the AE results for 
PLT (usually double 
PLT plus plasma or tri-
ple PLT). For compari-
son the system also 
provides AE percent 
values in brackets. 
These benchmark val-
ues arise from 9,157 
PLTs that were done in 
4 other centres in 2015.
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tains the specifications of the apheresis-related AE. All types of AEs 
are available in form of electronic index cards: AE in the context of 
‘puncture’ (BAI), ‘anticoagulation’ CT), ‘circulation’ (VVR), ‘donor 
events’, (DEs),’ technical events’ (TEs) and ‘miscellaneous events’ 
(MEs). If one of these electronic index cards is activated by a click 
into the corresponding square click box, a tripartite submenu opens 
with the structure: symptoms typically associated with the AE that 
entitled the index card, possible interventions of the apheresis op-
erator or donor physician to treat the AE and a free-text area for a 
brief comment to the AE (optional). The BAI (fig.  3) and VVR 
(fig. 4a) symptoms are given in a way that all features of the latest 
IHN Standard for Surveillance of Complications Related to Blood 
Donation are represented [24]. Although they are not a topic of the 
IHN standard, we also included DEs (not shown) and TEs. DEs 
comprise blood count abnormalities (e g. leucocytosis, low platelet 
counts) and donor compliance problems that might cause a break-
off. TEs include a variety of machine-, software- or disposable-re-
lated shortcomings because they occasionally cause significant dif-
ficulties and/or break-offs during haemaphereses (fig. 4b).
Automated Grading of AEs
The haemapheresis vigilance system classifies symptoms as 
‘mild’, ‘moderate’ or ‘severe’ without any user interaction accord-
ing to an internal algorithm that includes symptom severity as well 
as staff interventions. To illustrate the function of this algorithm, 
we here present three examples: An uncomplicated haemapheresis-
related small haematoma with a diameter of 20–50 mm is graded as 
a ‘mild’ symptom. However, if the donor requires external medical 
help outside the apheresis unit for haematoma treatment (e.g. be-
cause a branch of the brachial artery was hurt), it is classified as a 
‘severe’ complication. CT symptoms responding quickly to calcium 
orally are considered to be ‘mild’. If intravenous (i.v.) calcium is 
required however, the grading increases to ‘moderate’, or even to 
severe if relatively large amounts of i.v. calcium (˰3 ampoules) 
have to be administered. An uncomplicated loss of consciousness 
(LOC) on-side the apheresis unit, without any further harm for the 
donor, is graded as ‘mild’, if it lasts less than 60 s, and as ‘moderate’ 
in case of a LOC > 60 s. However, a LOC outside the apheresis unit, 
even if it happens without any harm for the donor, is considered to 
be a ‘severe’ reaction as it potentially threatens a donor to a much 
higher degree than the same reaction on-side the unit. 
Automated Evaluation of AEs
The centre administrator is qualified to start the evaluation pro-
gramme for his specific centre. The AEs are evaluated for each type 
of apheresis procedure separately (e. g. PLT or PLS or SC apheresis 
etc.). Evaluations are possible for a time span ranging from 1 
month to 1 calendar year. The AE results emerge either as absolute 
numbers or as relative numbers (percent values). Data evaluation 
follows the IHN standard (December 2014) and the AGHV pre-
settings (June 2016). IHN standard evaluation data are shown in 
the sequence and order of the IHN standard (upper part of the 
‘Evaluation Data’ HTML page, from A (Local Symptoms) to F 
(Other AE), see fig. 5). The specific AGHV evaluation pre-settings 
are given on the lower part of the Evaluation Data HTML page, see 
figure 6. In this part the data are presented in the order SAE, break-



Fig. 6.  Automated evaluation according to AGHV standard (here: break-off during PLT, detail). Data from Hanover Medical School 2015 as an example for the 
function of the system. The automated evaluation does not only comprehend break-offs, but also reasons for break-offs (puncture-, citrate toxicity (anticoagula-
tion)-, circulation-related etc.), the type of PLT procedures that were involved in the break-off (single, double or triple PLT) and a comparison between the numbers 
of planned blood products at start of PLT versus the numbers of blood products that had been already obtained when the PLT had to be terminated.
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offs, planned blood products versus obtained blood products de-
spite break-off, and demographic donor data. The evaluation pro-
cess takes place within approximately 60 s for the absolute AE 
numbers as well as for the relative AE numbers (percent calcula-
tions including the corresponding benchmark results that are given 
as percent values in brackets. For example, mild VVR from 5,990 
combined PLT/PLS in Hanover in 2015 occurred at a rate of 0.25% 
compared to 0.29% as benchmark result from  9,157 PLT proce-
dures that were performed in four other participating centres in 
2015 (fig. 5, see line B total: Total number of vasovagal reactions). 
A detail for the depth of the evaluation according to the AGHV 
pre-settings is given in figure 6. This kind of automated evaluation 
does not only comprise break-offs but also reasons for break-offs 
(puncture-, CT(anticoagulation)-, circulation-related etc.), the type 
of PLT procedures that were involved in break-offs (single, double 
or triple PLT) and a comparison between the numbers of planned 
blood products at start of PLT versus the numbers of blood prod-
ucts that could be obtained at the time when the PLT had to be 
terminated .
Preliminary Multi-Centre Study Results
To give the reader an impression of the power and quality of the 
collected data and of the performance of the system, here we pre-
sent a short overview of data entry from all centres that participate 
in the multi-centre trial. From January 2012 to December 2015 the 
on-line haemapheresis vigilance system collected 16,744 AEs out of 
approximately 345,000 haemaphereses (4.9%). The majority of the 
AEs occurred in preparative PLSs (63%, see table 2), followed by 
PLTs at 34.5% and blood SC aphereses at 2.2%. BAIs account for 
about 55% of the supplied AEs. DEs (e.g., blood count irregulari-
ties, lipaemic plasma, termination of the procedure at the request 
of the donor), anticoagulation (CT) symptoms or circulation com-
plications equally affected haemaphereses at about 11–15%, 
whereas TEs (e.g., disposable leakages, hardware or software crash) 
narrowed 10% (table 3). Out of 12,348 finalized AEs, 8,759 (70.1%) 
were associated with a break-off of the procedure (table 4). Inter-
estingly, CT-related AEs had the lowest relative break-off rate, 
 indicating that this type of AE is easier to manage than other 
complications.
Discussion
International as well as German regulations prescribe to assess 
and to evaluate donor complications in blood donation carefully 
[25, 26]. Our on-line haemapheresis vigilance system was designed 
as a modern solution for assessment of these complications in the 
versatile field of preparative haemapheresis. The system is able to 
display virtually every routine apheresis procedure regardless 
which apheresis machine is used, which type of cells is collected or 
which combination of products (cellular products or plasma plus 
cellular blood components) are obtained (fig. 1, 2). With respect to 
complication data, our system is able to assess all possible AEs in a 
way that the IHN Standard for Surveillance of Complications Re-
lated to Blood Donation is followed. As shown in figure 3, we have 
recently revised our system so that the 2nd edition of the IHN 
standard (effective from December 2014) with, e.g., rare but dan-
gerous puncture-related symptoms such as deep venous thrombo-
sis, arterio-venous fistula and brachial artery pseudoaneurysm and 
all other changes could be included. Another attractive feature of 
our on-line system is the automated evaluation. Here again the lat-
est version of the IHN standard was followed. This is shown by the 
arrangement of the symptoms shown on the upper part the evalua-
tion HTML page (fig. 5). The symptoms strictly follow the nomen-
Table 3. On-line haemapheresis vigilance system: Kind and frequency 
of AEs
Type of AE Frequency, n Frequency, %
Blood access 9,372  54.5
CT 1,894  11.0
Circulation 1,955  11.4
DEs  2,527  14.7
TEs 1,427   8.3
MEs 17   0.1
Total* 17,192* 100.0
*Including 478 aphereses with ‘double events’ (e.g., a ‘late’ haematoma at  
60 min after the start of the haemapheresis due to ‘motorical restlessness’  
(= uncontrolled arm movements) of the donor: blood access injury (event 1)  
plus donor compliance problem (event 2, ‘double events’).
Table 2. On-line haemapheresis vigilance system: allocation of AEs to type 
of apheresis procedure
Apheresis procedure Frequency Percent
PLS 10,565  63.03
PLT 5,769  34.52
SC 363   2.17
MNC 36   0.22
Erythrocytes 10   0.06
PMN 1   0.01
Total 16,744 100.00
Table 4. On-line haemapheresis vigilance system: Procedure-related break-
offs during haemaphereses
Type of AE Finalized* Break-off
n %
Blood access 6,955 5,463 78,5
CT 1,534 161 10,5
Circulation 1,385 1,002 72,3
DEs 1,535 1,425 92,8
TEs 937 707 75,5
Total 12,348 8,759 70,1
*Including finalized AE only, i.e., data accepted by a physician or another  
person with a higher password hierarchy and responsibility for donor care.
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clature and the order of the IHN standard 2014. A further strength 
of the system is the possibility to exactly assess whether an aphere-
sis procedure had to be prematurely terminated (fig.  3, table  4). 
This is an important specification as it makes a difference whether 
a procedure had to be finished a few minutes after the start of the 
apheresis (without any products obtained) or shortly before the in-
tended completion of the procedure (maybe with all planned prod-
ucts obtained, fig.3). 
The Open Prospective Multi-Centre Long-Term Study for As-
sessment of AEs in Haemaphereses via an On-Line Haemapheresis 
Vigilance System that underlies the system was designed as a 
7-year observational study. As some participating centres needed 
the first months in 2012 to start data assessment, the study will be 
presumably closed by June 30, 2019. A comprehensive and detailed 
publication of all study data is planned for 2020. Here we present a 
small subset of preliminary data, just to demonstrate the potential 
and the power of the system. From January 2012 to December 2015 
a total of 16,744 complications out of approximately 345,000 
haemaphereses (4.9%) were entered into the system by all partici-
pating centres. This value is in good accordance to other reports on 
donor complications in apheresis with a similarly large body of 
data [ 16, 20]. Preparative PLSs were most often affected (63%), fol-
lowed by PLTs (34.5%, table 5). This is not surprising as both PLSs 
and PLTs account for the apheresis techniques that are most often 
applied in Germany [6]. Of note, our system will probably assess 
more SAEs than previously reported [13–15, 23]. This is, at least 
in part, due to assessment of technical (e.g., disposable leakage) 
and donor characteristics typically associated with deferral from 
haemapheresis (e.g., blood count abnormalities). The latter ones 
are usually not part of donor haemovigilance systems but are also 
important to assess.
From the very beginning, our on-line haemapheresis vigilance 
system was aimed to fulfil three different purposes: 
– First and clearly most important, to provide a platform for com-
prehensive and easy assessment and automated evaluation of 
donor complications. 
– Second, to deliver basic information for staff education. For ex-
ample, haematoma are not only a question of donor safety but 
may also trigger a training course for single staff members or 
for the whole operator group. 
– Third, to numeralize potential economic losses that are associated 
with premature break-offs of haemaphereses. A break-off of a 
whole blood donation may charge a blood donation service with 
a relatively small amount in the range of EUR 10.00, if the blood 
bag system is considered. In contrast, a break-off in a haemapher-
esis will charge the apheresis unit with costs far beyond EUR 
100.00, if the apheresis disposable for a PLT is considered. 
Thus our on-line system provides assessment and evaluation 
tools to support apheresis units in the versatile and complex field 
of haemapheresis. 
Conclusions and Prospects
To our knowledge, we present here the first web-based system 
for assessment of AEs in haemaphereses that is based on the IHN 
Standard for Surveillance of Complications Related to Blood Do-
nation. The system is in operation since January 2012. It is working 
continuously and stable during an operation time of more than 4 
years. The system is going to be continuously developed. This is 
shown by the recent integration of the IHN standard 2014 update. 
It is comprehensive as all kind of preparative haemaphereses in-
cluding all conceivable product combinations, even in terms of MC 
apheresis, and all types of AEs can be supplied. It provides a relia-
ble grading of AE as it works with an internal algorithm that ex-
cludes a subjective operator-derived bias, thereby ensuring the 
comparability of the data. The system presents a unique and highly 
automated evaluation tool that offers a quick and comprehensive 
analysis of the centre-specific haemapheresis-related AEs within 
2–3 min. The evaluation tool has adopted the IHN standard, in-
cludes a benchmark function for comparison of AE data within the 
system and offers additional features such as break-off evaluation. 
HTML page Functions Examples, see figure
Title page start of data entry, search functions, access to system-related documents n.s.
Apheresis specification donor and procedure variables (overview) 1
  procedure variables (here plasmapheresis, stem cell apheresis) 2a,b
Complication data outcome and AE specification variables (overview) 3
blood access injury (‘puncture’) 3
vasovagal reaction (‘circulation’) 4a
technical problem (‘technics’) 4b
Centre administration default entry, start of evaluation n.s.
Apheresis numbers apheresis numbers, procedure-specific n.s.
Evaluation evaluation according IHN 2014 5
Evaluation evaluation according AGHV 2016 6
n.s. = Not shown.
Table 5. Composi-
tion of the on-line 
haemapheresis vigi-
lance system
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Our on-line haemapheresis vigilance platform is intended as a 
gradually growing system. Further developments may include the 
creation of interfaces to automate the import of, e.g., donor data or 
apheresis specifications and to establish data transfer to regulatory 
authorities in case of SAEs. Furthermore, in addition to the now 
available IHNstandard evaluation, other automated evaluation 
modes are being developed. These evaluation modes will be based 
on specific parameters (e.g., evaluation of VVR or CT in context 
with, e.g., donor body weight, gender and apheresis procedure) 
and will allow an even more detailed automated AE evaluation in 
haemaphereses.
Our on-line system offers a ‘low-threshold’ opportunity to assess 
and evaluate apheresis-related complications. Low threshold means 
that simple registration, predominantly self-explaining items and, 
as a non-profit project, reasonable costs facilitate the participation 
to the system. After appropriate registration the on-line access al-
lows every centre active in preparative aphereses from everywhere 
in the world to enter data into our system and to benefit from an 
automated evaluation according to internationally accepted stand-
ards. Theoretically, on-line registries like ours have the potential to 
overcome the variety of haemovigilance studies (as shown in 
table 1) with their widely incongruent and conflicting results.
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